A cross-sectional, web-based survey of physicians in breast cancer treatment to reveal the underserved patient population who do not receive CDK4/6 inhibitor plus endocrine therapy and to identify the challenges of the disparity in Japa
Not Applicable
- Conditions
- HR+/HER2- advanced breast cancer
- Registration Number
- JPRN-UMIN000050760
- Lead Sponsor
- Pfizer Japan Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
There are no exclusion criteria for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage share of each treatment option (e.g., CDK4/6 inhibitor plus endocrine therapy, hormone monotherapy, chemotherapy) as first-line treatment for patients with HR+/HER2- advanced breast cancer
- Secondary Outcome Measures
Name Time Method Challenges to prescribe CDK4/6 inhibitor plus endocrine therapy